Apparatus, methods, systems, etc., for the tangential flow filtration (TFF) of viscous compositions including viscous fluids, solutions, gels, pastes, creams and suspensions with viscosities greater than 10 cP, 20 cP, 50 cP or 100 cP. The methods, etc., provide enhanced mixing of the viscous compositions in their storage vessels by extracting the input composition from different depths in the storage vessels to reduce or eliminate vertical concentration gradients.

A composition having a non-polar fraction obtained from at least one fermented plant material is provided. The at least one plant material has been subjected to a lactic acid fermentation.

A composition having a non-polar fraction obtained from at least one fermented plant material is provided. The at least one plant material has been subjected to a lactic acid fermentation.

A composition having a non-polar fraction obtained from at least one fermented plant material is provided. The at least one plant material has been subjected to a lactic acid fermentation.

A medicament for use in treating hypertension. The medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A medicament for use in treating hypertension. The medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A medicament for use in treating hypertension. The medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

The present invention is concerned with boosting innate immunity in animals with an immune system that includes an alternative complement pathway in which they are fed an effective amount of a red seaweed of Asparagopsis species.

The present invention is concerned with boosting innate immunity in animals with an immune system that includes an alternative complement pathway in which they are fed an effective amount of a red seaweed of Asparagopsis species.

Pharmaceutical compositions are described comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of coronavirus infection in a human. Particularly, the viral infection is OC43 or SARS-CoV-1 or SARS-CoV-2 infection. There are also described Pharmaceutical compositions comprising fucoidan for use in a method for prevention coronavirus spread in a human population, wherein subjects of the population are tested for infection with OC43 or SARS-CoV-1 or SARS-CoV-2 and infected subjects are treated with intranasal administration of the Pharmaceutical composition.